Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins

• Published in: F1000 research Vol. 6; p. 587
• Main Authors: Finlay, Darren, Teriete, Peter, Vamos, Mitchell, Cosford, Nicholas D P, Vuori, Kristiina
• Format: Journal Article
• Language: English
• Published: England Faculty of 1000 Ltd 2017; F1000Research; F1000 Research Ltd
• Subjects: Apoptosis; Cancer Therapeutics; Cell Growth & Division; Cellular Death & Stress Responses; Drug Discovery & Design; Molecular Pharmacology; Review; inhibitor of apoptosis proteins; IAPs; apoptosis; cancer; tumours
• ISSN: 2046-1402; 2046-1402
• DOI: 10.12688/f1000research.10625.1

The heterogeneous group of diseases collectively termed cancer results not just from aberrant cellular proliferation but also from a lack of accompanying homeostatic cell death. Indeed, cancer cells regularly acquire resistance to programmed cell death, or apoptosis, which not only supports cancer progression but also leads to resistance to therapeutic agents. Thus, various approaches have been undertaken in order to induce apoptosis in tumor cells for therapeutic purposes. Here, we will focus our discussion on agents that directly affect the apoptotic machinery itself rather than on drugs that induce apoptosis in tumor cells indirectly, such as by DNA damage or kinase dependency inhibition. As the roles of the Bcl-2 family have been extensively studied and reviewed recently, we will focus in this review specifically on the inhibitor of apoptosis protein (IAP) family. IAPs are a disparate group of proteins that all contain a baculovirus IAP repeat domain, which is important for the inhibition of apoptosis in some, but not all, family members. We describe each of the family members with respect to their structural and functional similarities and differences and their respective roles in cancer. Finally, we also review the current state of IAPs as targets for anti-cancer therapeutics and discuss the current clinical state of IAP antagonists.